Weight management · 5 min read · Evidence-informed guide
Compounded GLP-1 Medicines: What FDA Approval Means
Compounded semaglutide and tirzepatide products are not FDA-approved finished drugs. FDA does not review compounded products for safety, effectiveness, or quality before marketing, and says compounded drugs should be used only when a patient’s medical need cannot be met by an approved drug.
Key answer
The short version
Compounded semaglutide and tirzepatide products are not FDA-approved finished drugs. FDA does not review compounded products for safety, effectiveness, or quality before marketing, and says compounded drugs should be used only when a patient’s medical need cannot be met by an approved drug.
Compounded is not generic
An FDA-approved generic must meet FDA standards for approval. A compounded preparation is different: it is prepared under specific legal and clinical circumstances and should not be represented as identical to an approved brand product.
Source and dose are safety issues
FDA has reported concerns about dosing errors, counterfeit or illegally marketed products, and salt forms of semaglutide that differ from the active ingredient in approved medicines. Use a prescription and a state-licensed pharmacy.
Ask precise questions
Ask whether the product is FDA-approved or compounded, who dispenses it, what the exact active ingredient and concentration are, what instructions apply, and why a compounded product is being considered.
Clinical perspective
How to think about this
Prescription weight management is longitudinal medical care, not a consumer transaction. A sound plan weighs approved use, safety, nutrition, access, follow-up, and the patient’s own goals; it should never reduce a complex health decision to a promised outcome or a single number on a scale.
Questions worth bringing to a visit
- What FDA-approved option, if any, fits my clinical situation?
- What safety monitoring and follow-up would I need?
- How will we assess benefit, tolerability, and access over time?
Continue exploring
Related patient questions
Sources
1. FDA, Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
FDA distinction between approved and unapproved GLP-1 products.
2. FDA, Dosing errors with compounded injectable semaglutide
Dosing and product-source safety concerns.